Aurinia Pharmaceuticals I...
(AUPH)
undefined
undefined%
At close: undefined
9.37
0.00%
After-hours Dec 13, 2024, 07:01 PM EST
Company Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.
| Country | CA |
| IPO Date | Sep 3, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Peter S. Greenleaf M.B.A. |
Contact Details
Address: 4464 Markham Street Victoria, BC CA | |
| Website | https://www.auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter S. Greenleaf M.B.A. | Chief Executive Officer & Director |
| Joseph M. Miller CPA | Chief Financial Officer |
| Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations |
| DeDe Sheel | Vice President of Investor Relation |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing & Supply Chain |
| Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Michael R. Martin | Chief Business Officer |
| Stephen P. Robertson | Executive Vice President of General Counsel |
| Sue Evans | Senior Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 4 | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | 3 | Filing |